Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’May 5, 2023Rheumatoid Arthritis
FDA puts partial hold on investigational alopecia areata drug deuruxolitinibMay 4, 2023Rheumatoid Arthritis
Researchers seek to understand post-COVID autoimmune disease riskMay 1, 2023COVID-19 UpdatesLong COVIDRheumatoid ArthritisLupus & Connective Tissue Diseases
Meta-analysis examines cancer risk concern for JAK inhibitorsApril 26, 2023Rheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisPediatricsAnkylosing spondylitis
Registry data ‘reassure’ on biologics’ heart attack risk in rheumatoid arthritisApril 25, 2023Rheumatoid Arthritis
Biosimilars and patients: Discussions should address safety, cost, and anxiety about changeMarch 30, 2023Business of MedicineRheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisPediatricsLupus & Connective Tissue DiseasesAnkylosing spondylitis
FDA approves new formulation of Hyrimoz adalimumab biosimilarMarch 27, 2023Rheumatoid ArthritisPsoriatic ArthritisPediatricsAnkylosing spondylitisSpondyloarthropathies
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatologyMarch 19, 2023Rheumatoid Arthritis
FDA approves first biologic treatment for polymyalgia rheumaticaMarch 1, 2023Lupus & Connective Tissue DiseasesRheumatoid Arthritis
Bacteremia, antibodies link periodontal disease to RA development and activityFebruary 28, 2023Rheumatoid Arthritis
What’s holding back physicians from prescribing biosimilars? Four specialties weigh inFebruary 23, 2023Business of MedicineAnkylosing spondylitisPsoriatic ArthritisRheumatoid ArthritisSpondyloarthropathiesPediatrics
